Guidelines for IHC markers (i.e. ER, PR, HER2, Ki67) evaluation are continuously under discussion to stratify breast cancer patients in a clinical context for prognostic and treatment selection purposes [6-8]. This evidence concerns the gene PGR and breast carcinoma.